Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU Patients

Results Expected to Promote Awareness and Adoption of PKU GOLIKE

GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2024

RELIEF THERAPEUTICS Holding SA (SIX:RLF )(OTCQB:RLFTF )(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the full readout and compelling results from the clinical trial evaluating PKU GOLIKE as a protein substitute for the treatment of phenylketonuria (PKU) in patients during prolonged fasting periods. The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels, both essential for brain function and metabolic health.

This groundbreaking research showcases the potential of PKU GOLIKE to revolutionize the management of PKU patients, particularly during extended fasting periods. By effectively controlling metabolite levels, this innovative protein substitute offers a promising alternative to current standard treatments, ultimately enhancing the overall well-being and quality of life for individuals living with PKU.

Furthermore, the results of this clinical trial are expected to raise awareness about the importance of metabolic control in individuals with PKU and promote the adoption of PKU GOLIKE as a preferred therapeutic option. The efficacy and safety demonstrated in this study highlight the significant impact that this novel protein substitute can have on improving health outcomes and optimizing care for PKU patients.

Impact on Individuals

For individuals with PKU, the findings of this clinical trial offer hope for better management of their condition and improved metabolic control. By incorporating PKU GOLIKE into their treatment regimen, patients may experience enhanced control over phenylalanine levels, leading to better cognitive function and overall health outcomes.

Global Implications

The positive results of this study have the potential to revolutionize the standard of care for PKU patients worldwide. By promoting the awareness and adoption of PKU GOLIKE, healthcare providers can offer a more effective and personalized approach to managing this rare genetic disorder, ultimately improving the quality of life for individuals affected by PKU on a global scale.

Conclusion

In conclusion, the results of the clinical trial evaluating PKU GOLIKE demonstrate its superior metabolic control during prolonged fasting in PKU patients. These findings are expected to have a profound impact on the management of PKU and drive the adoption of this innovative protein substitute as a preferred treatment option. By improving metabolic control and enhancing health outcomes for individuals with PKU, PKU GOLIKE has the potential to revolutionize care practices and promote better quality of life for patients worldwide.